Meryl Aaron, APRN
Psychiatric/Mental Health · Edmond, OKNPI 1477117638
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.3% of it on its own, with 24 other manufacturers making up the rest. Among psychiatric/mental health clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 524 payments — averaging $43.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$883
- Teva Pharmaceuticals USA, Inc.$504
- Takeda Pharmaceuticals U.S.A., Inc.$487
- plus $4K from 19 others
What the payments were for
- Speaking & faculty fees$12,00053%
- Travel & lodging$2621%
- Food & beverage$10,34945%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 133 | $13,968 |
| Johnson & Johnson | 87 | $1,934 |
| Otsuka America Pharmaceutical, Inc. | 54 | $1,427 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $883 |
| Teva Pharmaceuticals USA, Inc. | 14 | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $487 |
| Axsome Therapeutics, Inc. | 30 | $428 |
| Insmed, Inc. | 2 | $350 |
| Corium, LLC | 13 | $326 |
| Supernus Pharmaceuticals, Inc. | 10 | $317 |
| Ironshore Pharmaceuticals Inc. | 14 | $315 |
| Neurocrine Biosciences, Inc. | 3 | $278 |
| Indivior Inc. | 19 | $268 |
| Alkermes, Inc. | 10 | $253 |
| Lundbeck LLC | 10 | $213 |
| Noven Therapeutics, LLC | 17 | $211 |
| E.r. Squibb & Sons, L.L.C. | 8 | $203 |
| Sunovion Pharmaceuticals Inc. | 5 | $90 |
| Idorsia Pharmaceuticals US Inc | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Braeburn Inc. | 3 | $62 |
| OWP Pharmaceuticals, Inc. | 2 | $39 |
| Almatica Pharma LLC | 2 | $38 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Livanova USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,789 in reported general payments places this provider in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 16 | $51,269 |
| PerserisRisperidone | 11 | $27,704 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,168 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $6,991 |
| Buprenorphine Hcl | 17 | $2,199 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $2,022 |
| Lamotrigine ErLamotrigine | 17 | $1,825 |
| Aripiprazole | 20 | $1,605 |
| Vilazodone Hcl | 15 | $1,556 |
| Lamotrigine | 64 | $892 |
| Buspirone Hcl | 32 | $854 |
| Fluvoxamine Maleate | 15 | $778 |
| Ziprasidone Hcl | 14 | $719 |
| Duloxetine Hcl | 40 | $692 |
| Olanzapine | 15 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,934 | $51,26916 claims |
| Indivior Inc.Perseris | $268 | $27,70411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $487 | $13,16819 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $10119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Edmond
- Amber BrownEdmond$15K
- Rebecca DanielEdmond$6K
- Joanna SmithEdmond$4K
- Cristen DegraffenreidEdmond$4K
- Fernanda CooleyTulsa$16K
- Amy BoggsNorman$15K
- Sylvie MawohOklahoma City$14K
- Nicole HolzerNorman$12K
- Pramila TraxlerTulsa$12K
- Sasha LounmalaMuskogee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.